Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropathix Inc (OP: NPTX )

N/A UNCHANGED
Last Price Updated: 12:23 PM EDT, Oct 19, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuropathix Inc

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Cannabis
Exposures Cannabis
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic... 
From Neuropathix, Inc.
Via AccessWire
Exposures COVID-19
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
Medical Marijuana, Inc. (OTCPK:MJNA) released its financial results for the quarter ending March 31, 2022, revealing $7.8 million in net revenue, a 24% increase when compared to the previous quarter.... 
Via Benzinga
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA / ACCESSWIRE / April 13,... 
From Neuropathix, Inc.
Via AccessWire
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO... 
From Neuropathix, Inc.
Via AccessWire
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
DOYLESTOWN, PA / ACCESSWIRE / January 25, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it... 
From Neuropathix, Inc.
Via AccessWire
Topics Cannabis Derivatives Intellectual Property
Exposures Cannabis Derivatives Intellectual Property
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
DOYLESTOWN, PA / ACCESSWIRE / November 17, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible life sciences company focused on the research and development... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Pharmaceutical Assets Include Company's Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company's Strategy is to Utilize the Phase 2 Study... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
DOYLESTOWN, PA / ACCESSWIRE / August 12, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the... 
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS